Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.

(1)

CORRECTION

Correction: Does the Chemotherapy

Backbone Impact on the Efficacy of Targeted

Agents in Metastatic Colorectal Cancer? A

Systematic Review and Meta-Analysis of the

Literature

David L. Chan, Nick Pavlakis, Jeremy Shapiro, Timothy J. Price, Christos S. Karapetis,

Niall C. Tebbutt, Eva Segelov

There is an error in reference 22. The correct reference is: Peeters M, Price TJ, Cervantes A,

Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with

fluorouracil, leucovorin, and irinotecan(FOLFIRI) compared with FOLFIRI alone as

second-line treatment in patients with metastaticcolorectal cancer. J Clin Oncol. 2010 Nov 1;28(31):

4706-13.

Fig 5

is incorrect. The authors have provided a corrected version here.

PLOS ONE | DOI:10.1371/journal.pone.0138916 September 25, 2015 1 / 2

OPEN ACCESS

Citation:Chan DL, Pavlakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, et al. (2015) Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS ONE 10(9): e0138916. doi:10.1371/journal.pone.0138916

Published:September 25, 2015

(2)

Reference

1. Chan DL, Pavlakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, et al. (2015) Does the Chemo-therapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Sys-tematic Review and Meta-Analysis of the Literature. PLoS ONE 10(8): e0135599. doi:10.1371/journal. pone.0135599PMID:26275292

Fig 5. OS outcomes for EGFR-I by chemotherapy backbone—extended RAS analysis.

doi:10.1371/journal.pone.0138916.g001